βARK1 inhibition improves survival in a mouse model of heart failure induced by myocardial infarction

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 3, 2004, Pages 329-334

  Suzuki, Yoshiyuki ^a   Nakano, Kiyotaka ^a   Sugiyama, Masakazu ^a   Imagawa, Jun Ichi ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

adrenergic receptor kinase; adrenergic receptor signaling; Echocardiography; Heart failure; Myocardial infarction; Survival

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR KINASE 1; BETA ADRENERGIC RECEPTOR KINASE 1 INHIBITOR; PHOSPHOTRANSFERASE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME INHIBITION; GENE THERAPY; HEART; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SIGNAL TRANSDUCTION; SURVIVAL; WILD TYPE; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CORONARY ARTERY OBSTRUCTION; DIASTOLE; DISEASE MODEL; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART RUPTURE; HETEROZYGOTE; HOMOZYGOTE; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SYSTOLE; TRANSGENIC MOUSE;

ANIMALS; BETA-ADRENERGIC RECEPTOR KINASE; CORONARY STENOSIS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIASTOLE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HEART FAILURE, CONGESTIVE; HEART RUPTURE, POST-INFARCTION; HETEROZYGOTE; HOMOZYGOTE; HYPERTROPHY, LEFT VENTRICULAR; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SYSTOLE;

EID: 4344646716     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000134776.70798.44     Document Type: Article

References (35)

1. Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet. 1998;352(Suppl I):8-14.
2. Ungerer M, Bohm M, Elce J, et al. Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptor in the failing human heart. Circulation. 1993;87:454-463.
3. Ungerer M, Parutti G, Bohm M, et al. Expression of β-arrestins and β-adrenergic receptor kinases in the failing human heart. Circ Res. 1994;74: 206-213.
4. Cho MC, Rapacciuolo A, Koch WJ, et al. Defective β-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression. J Biol Chem. 1999;274: 22251-22256.
5. Choi DJ, Koch WJ, Hunter JJ, et al. Mechanism of β-adrenergic receptor desensitization in cardiac hypertrophy is increased β-adrenergic receptor kinase. J Biol Chem. 1997;272:17223-17229.
6. Ishigai Y, Mori T, Moriyama S, et al. Induction of cardiac β-adrenergic receptor kinase 1 in rat heart failure caused by coronary ligation. J Mol Cell Cardiol. 1999;31:1261-1268.
7. Maurice JP, Shah AS, Kypson AP, et al. Molecular β-adrenergic signaling abnormalities in failing rabbit hearts after infarction. Am J Physiol. 1999; 276:H1853-H1860.
8. Rockman HA, Chien KR, Choi DJ, et al. Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA. 1998;95:7000-7005.
9. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu Rev Biochem. 1998;67:653-692.
10. Koch WJ, Inglese J, Stone WC, et al. The binding site for the βγ subunits of heterotrimetric G proteins on the β-adrenergic receptor kinase. J Biol Chem. 1993;268:8256-8260.
11. Koch WJ, Rockman HA, Samama P, et al. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor. Science. 1995;268:1350-1353.
12. Arber S, Hunter JJ, Ross J Jr, et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 1997;88:393-403.
13. Harding VB, Jones LR, Lefkowitz RJ, et al. Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci USA. 2001;98:5809-5814.
14. Shah AS, White DC, Emani S, et al. In vivo ventricular gene delivery of a β-adrenergic receptor kinase inhibitor to the failing heart reserves cardiac dysfunction. Circulation. 2001;103:1311-1316.
15. White DC, Hata JA, Shah AS, et al. Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci USA. 2000;97:5428-5433.
16. Du XJ, Gao XM, Ramsey D. Surgical methods of inducing transverse aortic stenosis and myocardial infarction in the mouse. Asia Pacific Heart J. 1998;7:187-192.
17. Gao XM, Dart AM, Dewar E, et al. Serial echocardiographic assessment of left ventricular dimensions and function after myocardial infarction in mice. Cardiovasc Res. 2000;45:330-338.
18. Patten RD, Aronovitz MJ, Deras-Mejia L, et al. Ventricular remodeling in a mouse model of myocardial infarction. Am J Physiol. 1998;274: H1812-H1820.
19. Du XJ, Gao XM, Jennings GL, et al. Preserved ventricular contractility in infarcted mouse heart overexpressing β2-adrenergic receptors. Am J Physiol. 2000;279:H2456-H2463.
20. Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac β-adrenergic receptors, and heart failure. Circulation. 2000;101:1634-1637.
21. Packer M. The development of positive inotropic agents for chronic heart failure: how have we gone astray? J Am Coll Cardiol. 1993;22(Suppl A):119A-126A.
22. Engelhardt S, Hein L, Wiesmann F, et al. Progressive hypertrophy and heart failure in beta 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA. 1999;96:7059-7064.
23. Iwase M, Bishop SP, Uechi M, et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gsa overexpression. Circ Res. 1996;78:517-524.
24. 2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation. 2000;101:1707-1714.
25. Farrell MH, Foody JM, Krumholz HM. Beta-blockers in heart failure: clinical applications. JAMA. 2002;287:890-897.
26. Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. JAMA. 2002;287:883-889.
27. Iaccarino G, Tomhave ED, Lefkowitz RJ, et al. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade. Circulation. 1998;98: 1783-1789.
28. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart failure. Nature. 2002;415:206-212.
29. Lefkowitz RJ. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. JBiol Chem. 1998;273:18677-18680.
30. Brodde OE. Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 1991;43:203-242.
31. Feldman AM. Experimental issues in assessment of G protein function in cardiac disease. Circulation. 1991;84:1852-1861.
32. Yu X, Zhang M, Kyker K, et al. Ischemic inactivation of G protein-coupled receptor kinase and altered desensitization of canine cardiac β-adrenergic receptors. Circulation. 2000;102:2535-2540.
33. Makino T, Hattori Y, Matsuda N, et al. Effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on β-adrenoceptor signaling in heart failure produced by myocardial infarction in rabbits: reversal of altered expression of β-adrenoceptor kinase and Giα. J Pharmacol Exp Ther. 2003;304:370-379.
34. Kiuchi K, Shannon RP, Komamura K, et al. Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest. 1993;91:907-914.
35. Sethi R, Bector N, Takeda N, et al. Alterations in G-proteins in congestive heart failure in cardiomyopathic (UM-X7.1) hamsters. Mol Cell Biochem. 1994;140:163-170.